Back

The efficacy and safety of hydroxychloroquine in patients with chronic inflammatory cardiomyopathy after fulminant myocarditis: a multicenter randomized study of the HYPIC trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Multidisciplinary care in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Wu He

Tongji Hospital- Tongji Medical College, Wuhan (China)

6 More presentations in this session

Presentation thumbnail
Impact of QRS duration on drug titration and left ventricular recovery in new-onset heart failure with reduced ejection fraction
Doctor A. Arenas Loriente (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
A decision algorithm for palliative care initiation in heart failure patients
Doctor I. Santos (Ponta Delgada, PT)
Abstract Slides Video
Presentation thumbnail
Effects of a dyadic empowerment-based heart failure management program (De-HF) on patient-reported and clinical outcomes: a double-blind randomized controlled trial
Doctor D. Yu (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Efficacy of early initiation of vericiguat in acute heart failure: a prospective study
Doctor J. Chen (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Vutrisiran reduces days lost to death and/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial
Doctor M. Hanna (Cleveland, US)
Abstract Slides Video

Access the full session

Session thumbnail
Multidisciplinary care in heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Hydroxychloroquine cures autoimmune myocarditis by inhibiting innate immune via the CXCL16-CXCR6 axis between macrophages and T cells
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on inflammation and immunity in cardiovascular disease
thumbnail
Congress Session
COVID-19 and the heart

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources